.png){kind=icon}
.png){kind=icon}
Return
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus
.png){kind=icon}
OA
AI
N
P
M
J
S
I
O
DOI：10.1002/bcp.70644.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed-dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated exposure metrics for QD and BID doses in paediatric patients and adults, and investigate the relationship between canagliflozin plasma concentrations and change from baseline HbA1c with QD and BID doses.
Keywords:
canagliflozin
diabetes mellitus
modelling
paediatrics
pharmacodynamics
pharmacokinetics
simulation
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3
Papers:
8.5K
Citations:
1.8W
Organization
Cited Papers